NTI

3.28%

5.9¢ neurotech international limited

Ann: Investor Presentation, page-114

First 114 Last

Share
Profile

Follow
Holmesearth01

7,533 Posts.

383

01/12/16

21:52

Post #: 21043793
Share

Originally posted by Lefevre ↑

Good to finally meet you Bonkers !
Impressive presentation. I could understand every word. Everything was clear and concise.
The path forward for sales is well structured and clear.

I liked the hearing aid comparison. Once you take the Cochlear implant out you still have the same hearing problem. Mente autism is the same. Once you stop using the headband the child will go back to his old ways.

Over 200 users currently. Some started 4 to 5 years ago. The information being gathered by recording electro physiological changes to the brain as opposed to a psychologist subjective observations is extremely valuable. They have already been approached from a couple of organisations about obtaining this data. This data will obviously be magnified in coming years with the huge step up in usage and its monetisation (don't think they have worked exactly how to yet) will be a key revenue source.

The commercial officer has hit the ground running and I would be expecting some fast results.
Their is a regulatory officer also appointed to deal with regulations on a global scale.
FDA trials about to start with the prestigious Carrick Institute which is a world leader in clinical neuroscience. The fact such a prestigious institute has taken these trials on is huge validation. I know from my RAP experience that these quality institutions only take on what they know will work and have a huge benefit to society.

In 2017 they will be finalising Mente pro and Mente Suite by the 4th quarter. Mente pro is a Clinical grade, medical device for clinical & research use. They already have hospitals waiting for this product.

I would like to say that Mente is a disruptive product but I can't because there is nothing to disrupt as there is no other product in this space.

The feeling I get is all the targets and deadlines they have set for next year are conservative and they aim to be ahead of each one.

With FDA approval in mid 2017, a growing sales pipeline, a product in the right space and the right capital structure NTI is set to really take off.

Cheers

Expand

Great post @Lefevre

Lots of good things to look forward to here

NTI Price at posting: 46.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

There are more pages in this discussion • 7 more messages in this thread...

First 114 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 5.9¢		Change -0.002(3.28%)		Mkt cap ! $61.04M

Open	High	Low	Value	Volume
6.0¢	6.1¢	5.9¢	$66.62K	1.114M

Buyers (Bids)

No.	Vol.	Price($)
3	112665	5.9¢

Sellers (Offers)

Price($)	Vol.	No.
6.1¢	70000	1

View Market Depth

No.	Vol.	Price($)
3	112665	0.059
8	634075	0.058
2	18313	0.057
2	47000	0.056
3	103000	0.055

Price($)	Vol.	No.
0.061	70000	1
0.062	193607	3
0.064	223386	2
0.065	82936	2
0.066	166666	1

Last trade - 15.36pm 27/09/2024 (20 minute delay)

NTI (ASX) Chart

Ann: Investor Presentation, page-114

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-114

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News